ATE370231T1 - Synthetische oligonukleotide die therapeutisch nützlich sind - Google Patents

Synthetische oligonukleotide die therapeutisch nützlich sind

Info

Publication number
ATE370231T1
ATE370231T1 AT00981117T AT00981117T ATE370231T1 AT E370231 T1 ATE370231 T1 AT E370231T1 AT 00981117 T AT00981117 T AT 00981117T AT 00981117 T AT00981117 T AT 00981117T AT E370231 T1 ATE370231 T1 AT E370231T1
Authority
AT
Austria
Prior art keywords
synthetic oligonucleotides
therapeutically useful
induction
group
caspases
Prior art date
Application number
AT00981117T
Other languages
English (en)
Inventor
Nigel Phillips
Mario Filion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE370231T1 publication Critical patent/ATE370231T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00981117T 1999-12-13 2000-12-12 Synthetische oligonukleotide die therapeutisch nützlich sind ATE370231T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17032599P 1999-12-13 1999-12-13
US22892500P 2000-08-29 2000-08-29

Publications (1)

Publication Number Publication Date
ATE370231T1 true ATE370231T1 (de) 2007-09-15

Family

ID=26865979

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00981117T ATE370231T1 (de) 1999-12-13 2000-12-12 Synthetische oligonukleotide die therapeutisch nützlich sind
AT07015976T ATE455851T1 (de) 1999-12-13 2000-12-12 Therapeutisch nützliche synthetische oligonukleotide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07015976T ATE455851T1 (de) 1999-12-13 2000-12-12 Therapeutisch nützliche synthetische oligonukleotide

Country Status (18)

Country Link
US (2) US7157436B2 (de)
EP (2) EP1238070B1 (de)
JP (1) JP4772245B2 (de)
KR (1) KR100829646B1 (de)
CN (2) CN100445380C (de)
AT (2) ATE370231T1 (de)
AU (1) AU785212B2 (de)
CA (1) CA2393808A1 (de)
CZ (1) CZ20022372A3 (de)
DE (2) DE60043759D1 (de)
DK (2) DK1867718T3 (de)
ES (2) ES2288883T3 (de)
HU (1) HUP0300627A3 (de)
IL (2) IL150196A0 (de)
MX (1) MXPA02005842A (de)
NO (1) NO330508B1 (de)
PT (1) PT1238070E (de)
WO (1) WO2001044465A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032610A1 (en) 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
EP1181304B1 (de) 1999-04-08 2007-10-10 Antisoma Research Limited Antiproliferative aktivität von g-reichen oligonukleotiden und verfahren um sie zur bindung an nukleotin zu verwenden
US7960540B2 (en) 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
WO2002018593A2 (en) 2000-08-29 2002-03-07 Bioniche Life Sciences Inc. Modulation of fas and fasl expression
ES2288883T3 (es) * 1999-12-13 2008-02-01 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
ATE398175T1 (de) * 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
DE60231986D1 (de) * 2001-08-17 2009-05-28 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
CN101160399A (zh) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
WO2004087203A2 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
CA2526212C (en) * 2003-05-16 2013-08-27 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
US20090209620A1 (en) * 2005-03-09 2009-08-20 Rong-Fu Wang Direct Reversal Of The Suppressive Function Of CD4+Regulatory T Cells Via Toll-Like Receptor 8 Signaling
WO2007028985A2 (en) * 2005-09-07 2007-03-15 The Secretary Of State For Defence Adjuvanted vaccine
EP2396408B1 (de) * 2009-02-12 2017-09-20 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem neurotrophen faktor gdnf mittels hemmung des natürlichen antisense-transkripts gegen gdnf
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
EP2490767A4 (de) * 2009-07-15 2013-02-13 Santaris Pharma As Auf gli2 abzielende rna-antagonisten zur behandlung von leukämie
CN104520439A (zh) * 2012-02-28 2015-04-15 国立大学法人东京农工大学 Tdp-43细胞内存在量关联疾患的认定方法
EP4000597A1 (de) * 2020-11-17 2022-05-25 The Boots Company plc Tetrapeptid und zusammensetzungen mit tetrapeptiden
WO2023122762A1 (en) * 2021-12-22 2023-06-29 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) * 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (de) * 1971-11-19 1975-02-07 Anvar
US4010257A (en) * 1973-02-23 1977-03-01 Burroughs Wellcome Co. Biological extracts
US3976544A (en) * 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) * 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) * 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) * 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) * 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) * 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) * 1984-02-17 1984-03-21 Stanford J L Biological preparations
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4744984A (en) * 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DE3723075A1 (de) * 1987-07-11 1989-01-19 Boehringer Mannheim Gmbh Eukaryotische expressionsvektoren mit multimeren enhancer-subelementen, verfahren zu ihrer herstellung und verwendung
US4958013A (en) * 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
WO1992007095A1 (en) * 1990-10-15 1992-04-30 Stratagene Arbitrarily primed polymerase chain reaction method for fingerprinting genomes
IL101038A0 (en) * 1991-02-21 1992-11-15 Gilead Sciences Inc Agent specific for trombin and its use
WO1998017320A1 (en) * 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US5474796A (en) * 1991-09-04 1995-12-12 Protogene Laboratories, Inc. Method and apparatus for conducting an array of chemical reactions on a support surface
IL107150A0 (en) * 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
JPH08508976A (ja) * 1993-01-29 1996-09-24 ベトレフアーム・インコーポレーテツド 改善化免疫療法用組成物
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CN1154702A (zh) * 1994-05-25 1997-07-16 海布里登公司 具有抗巨细胞病毒活性的寡核苷酸
NZ291734A (en) * 1994-08-30 1997-09-22 Commw Scient Ind Res Org Plant transcription regulators from circovirus; isolated nucleic acid molecules and transgenic plants
US5643890A (en) 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
IN181358B (de) * 1995-02-14 1998-05-30 Bioniche Inc
ZA964446B (en) * 1995-06-06 1996-12-06 Hoffmann La Roche Oligonucleotides specific for hepatitis c virus
US5990299A (en) * 1995-08-14 1999-11-23 Icn Pharmaceuticals, Inc. Control of CD44 gene expression for therapeutic use
JPH11507245A (ja) * 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
IT1277025B1 (it) * 1995-12-04 1997-11-04 Cooperativa Centro Ricerche Po Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
DE69738454D1 (de) * 1996-05-20 2008-02-21 Us Gov Health & Human Serv Oligonukleotide welche spezifisch retrovirale nukleokapsid-proteine binden
HU227921B1 (hu) * 1997-08-05 2012-06-28 Bioniche Life Sciences Inc Készítmény és eljárás sejtproliferáció és sejtpusztulás szabályozására
US6255473B1 (en) * 1997-08-29 2001-07-03 Duke University Presenilin-1 gene promoter
OA12028A (en) * 1999-09-25 2006-04-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US20020091095A1 (en) * 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
ES2288883T3 (es) * 1999-12-13 2008-02-01 Bioniche Life Sciences Inc. Oligonucleotidos sinteticos utiles terapeuticamente.
JP4215429B2 (ja) * 1999-12-28 2009-01-28 バイオニケ ライフ サイエンシーズ インコーポレイテッド 癌治療におけるヒアルロン酸
AU2002341264B2 (en) * 2001-10-03 2007-07-12 Bioniche Life Sciences Inc. Therapeutically useful triethyleneglycol cholesteryl oligonucleotides
CN101160399A (zh) * 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用

Also Published As

Publication number Publication date
DE60036019D1 (de) 2007-09-27
US20010041681A1 (en) 2001-11-15
US20070213291A1 (en) 2007-09-13
WO2001044465A2 (en) 2001-06-21
NO330508B1 (no) 2011-05-09
DE60036019T2 (de) 2008-05-29
AU785212B2 (en) 2006-11-09
KR20020079752A (ko) 2002-10-19
EP1238070A2 (de) 2002-09-11
NO20022820D0 (no) 2002-06-13
ES2340807T3 (es) 2010-06-09
CA2393808A1 (en) 2001-06-21
HUP0300627A2 (hu) 2004-06-28
AU1847901A (en) 2001-06-25
CN101491536A (zh) 2009-07-29
DE60043759D1 (de) 2010-03-11
ATE455851T1 (de) 2010-02-15
US7157436B2 (en) 2007-01-02
IL150196A (en) 2009-06-15
DK1238070T3 (da) 2007-12-03
EP1867718A2 (de) 2007-12-19
JP4772245B2 (ja) 2011-09-14
ES2288883T3 (es) 2008-02-01
JP2003517041A (ja) 2003-05-20
CZ20022372A3 (cs) 2002-11-13
CN1433469A (zh) 2003-07-30
KR100829646B1 (ko) 2008-05-16
MXPA02005842A (es) 2003-10-14
NO20022820L (no) 2002-08-08
CN101491536B (zh) 2012-07-04
HUP0300627A3 (en) 2005-11-28
EP1867718A3 (de) 2008-04-02
WO2001044465A3 (en) 2001-11-29
CN100445380C (zh) 2008-12-24
IL150196A0 (en) 2002-12-01
DK1867718T3 (da) 2010-04-12
EP1867718B1 (de) 2010-01-20
PT1238070E (pt) 2007-11-06
EP1238070B1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
ATE370231T1 (de) Synthetische oligonukleotide die therapeutisch nützlich sind
EP0666923A4 (de) Gezielte bereitstellung von poly- oder oligonukleotiden in zellen.
GB2363874B (en) Bioinformatic transaction scheme
EP0659209A4 (de) Krebstherapie unter verwendung maligner zellen.
HUP0302345A3 (en) Novel triazolo pyrimidine compounds, their intermediates and process for their preparation
TW453437U (en) Bulletproof vest
EP1142591A4 (de) Genträger
WO2002036601A3 (en) Phase transfer catalyzed glycosidation of an indolocarbazole
AU7720800A (en) Engineered radiation resistant bioremediating bacteria
ZA9811378B (en) Graft copolymers as gene carriers.
GB9807114D0 (en) Novel process
IL163672A0 (en) Microorganisms as carriers of nucleotide sequencescoding for cell antigens used for the treatment o f tumors
GB9920816D0 (en) Plant gene
ZA962066B (en) Preparation of 4,6-dimethoxy-2-(phenoxycarbonyl)amino-pyrimidine.
GB9917109D0 (en) Plant genes
GB0026844D0 (en) Process and intermediates to a tetrahydro-[1,8]-naphthyridine
GB9914600D0 (en) Novel,process
ITMI920892A1 (it) Selezione genica in vitro mediante vettori ad rna
GB9921938D0 (en) Target for antiviral therapy
EP0533926A4 (de) Nukleotidderivat.
CA95581S (en) Hat
ITMI911430A1 (it) Composizione vetrosa ceramizzabile adatta per il rivestimento di manufatti ceramici, in particolare piastrelle.
ITMI991513A0 (it) Piastra radiante per panificazione
ZA99485B (en) Inhibition of cytokine production.
GB9930394D0 (en) Plant gene

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1238070

Country of ref document: EP